Although EPO has been approved for the treatment of renal anemia and has been successfully tested in multiple preclinical and clinical trials addressing different neurological diseases [36–42], the underlying mechanisms of EPO-conveyed cytoprotection remain poorly understood. Here, EPO is linked to nervous system disorder.